EMUC25 special: Dr. Rescigno talks about single agent TKI in selected mRCC patients

from EAU Podcasts · host European Association of Urology

UROONCO RCC associate editor Assoc. Prof. Carlotta Palumbo (IT) talks with medical oncologist Dr. Pasquale Rescigno (GB) about his presentation supporting the 'yes' position in the debate at EMUC25: “Is single agent TKI (tyrosine kinase inhibitor) still an option in selected mRCC patients? This interview was recorded at EMUC25 in Prague. For more updates on kidney cancer, please visit our educational platform UROONCO RCC.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Episode metadata supplied by the publisher feed · Published Nov 18, 2025

Embed this episode

Attribution link and audio player

NOW PLAYING

EMUC25 special: Dr. Rescigno talks about single agent TKI in selected mRCC patients

0:00 8:14

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of EAU Podcasts?

This episode is 8 minutes long.

When was this EAU Podcasts episode published?

This episode was published on November 18, 2025.

Can I download this EAU Podcasts episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!